The intricate process of aging, a universal yet highly individualized journey, is now understood to be significantly influenced by a fundamental malfunction within the body’s defense system, as revealed by groundbreaking research from Stanford Medicine. This extensive investigation, encompassing studies on both laboratory mice and human cellular models, has identified a specific deficiency in a crucial type of immune cell that may serve as a primary driver of age-related decline across the entire organism.
At the heart of this discovery lies the tissue-resident macrophage, a long-lived immune cell that establishes its permanent home within various organs. The research demonstrates that as these macrophages age, their capacity to effectively clear out another class of aging immune cells diminishes substantially. This decline in efferocytosis, the process by which cells engulf and remove cellular debris, appears to be a key contributor to the systemic aging observed throughout the body.
Remarkably, when scientists intervened to block a specific receptor, known as EP2, located on the surface of these tissue-resident macrophages, a cascade of beneficial effects was observed. In mice, multiple organ systems exhibited a striking retention of youthful characteristics. This rejuvenation was evident in vital areas such as the brain, heart, both cardiac and skeletal muscle, liver, spleen, bone marrow, kidneys, and colon. The EP2 receptor, it was found, typically responds to a hormone intricately linked to inflammation and pain signaling in both mammalian species.
The strategic disabling of the EP2 receptor, specifically within the tissue-resident macrophage population, conferred significant protection upon the mice. They demonstrated enhanced resilience against several debilitating conditions commonly associated with chronic inflammation and aging, including a reduction in frailty, less accumulation of excess body fat, and improved cardiovascular health. Furthermore, a notable mitigation of cognitive decline was reported by Dr. Katrin Andreasson, a distinguished professor of Neurology and Neurological Sciences at Stanford. "We have long sought to unravel the fundamental reasons behind aging," Dr. Andreasson stated, "and this research offers compelling evidence that a significant factor lies within this specific immune pathway." The comprehensive findings of this pioneering study have been formally documented in the esteemed scientific journal Science, with Dr. Andreasson serving as the senior author and Dr. Jessy Tan, an instructor in neurology, leading the research team.
These revelations offer profound new insights into the pivotal role that persistent, systemic inflammation plays in the aging process and the constellation of health challenges it engenders. More importantly, the study illuminates a potential therapeutic avenue that could significantly decelerate age-related deterioration in organ function and potentially extend the period of healthy lifespan in humans.
To fully appreciate the significance of these findings, it is essential to understand the immune system’s natural process for eliminating aged and defunct cells. The body’s initial line of defense against foreign invaders, such as bacteria and viruses, is spearheaded by neutrophils, the most abundant type of white blood cell. Originating in the bone marrow, these highly mobile cells circulate throughout the bloodstream, constantly vigilant for threats. Upon encountering pathogens, neutrophils can deploy potent antimicrobial substances and, in a self-sacrificing act, release web-like structures of biological material to ensnare and neutralize microbes.
Neutrophils are characterized by their relatively short lifespan, typically existing for around 12 to 24 hours. A substantial majority of these cells, approximately 90%, eventually find their way to organs like the liver, spleen, and bone marrow, where they are systematically removed by other immune cells. This clearance mechanism becomes critically important with advancing age. In older animals, a significant proportion of neutrophils that have not encountered a pathogen enter a state of senescence, a dysfunctional condition where they can release inflammatory compounds that damage surrounding tissues. The overall number of neutrophils tends to increase with age, and a growing percentage of these cells exhibit this senescent profile. "Senescent neutrophils actively contribute to tissue damage," Dr. Andreasson explained, "making their efficient removal paramount for preventing chronic inflammation."
Macrophages, in their multifaceted role, are the primary custodians responsible for this vital cellular cleanup. These adaptable immune cells not only combat infections and orchestrate the actions of other immune components but also secrete growth factors that promote the repair of damaged tissues. A key function of macrophages is the removal of dead and senescent cells, essentially acting as the body’s biological waste management system. "They are the cleanup crew of the body, and a significant portion of the debris they handle consists of defunct cells," Dr. Andreasson elaborated. The daily removal of senescent neutrophils alone represents a colossal task, with an estimated 100 billion such cells requiring clearance each day.
Macrophages exist in various forms, but the focus of this research is on tissue-resident macrophages. These are exceptionally long-lived cells that migrate to specific organs during embryonic development and remain there throughout an organism’s life, adapting to perform specialized functions within their local environment. One of their most critical responsibilities is the engulfment of senescent cells, with senescent neutrophils identified as particularly significant targets. Approximately 100 billion neutrophils are produced daily, and they begin to exhibit signs of senescence within 8 to 12 hours of entering circulation. Even neutrophils that haven’t fully entered senescence but have reached the end of their functional lifespan, signaling their own demise, become targets for clearance.
The central problem identified by the research is that tissue-resident macrophages themselves undergo a decline in function with age. Previous studies by Dr. Andreasson’s group had already indicated that these long-lived immune cells become increasingly susceptible to inflammation as organisms age, paradoxically contributing to the inflammatory environment they are meant to combat.
This age-related decline in macrophage function is significantly mediated by prostaglandins, a group of hormone-like lipids produced by immune cells. Specifically, a subtype known as PGE2 plays a crucial role. The effects of PGE2 are dependent on the specific receptors present on target cells. The EP2 receptor, a known mediator of inflammation, is found in high concentrations on tissue-resident macrophages. PGE2 production naturally escalates in response to infection, injury, and exposure to toxins, including compounds generated during the aging process. The researchers’ prior work established that PGE2 levels rise substantially over time, coinciding with an increase in EP2 expression on tissue-resident macrophages. This confluence creates a detrimental feedback loop: elevated PGE2 repeatedly activates the EP2 receptors on these macrophages, progressively impairing their ability to engulf and clear senescent neutrophils. Consequently, senescent neutrophils begin to accumulate in the bloodstream and tissues, exacerbating inflammation. Dr. Andreasson further noted that the metabolic efficiency of tissue-resident macrophages also deteriorates with age, leading to a steady decline in their performance. The current study posits that EP2 is a critical linchpin in this functional degradation. "We have demonstrated that when tissue-resident macrophages are genetically engineered to lack EP2, or when this receptor is blocked by a pharmacological agent, this age-related decline is prevented," she explained.
To meticulously investigate the role of the EP2 receptor, Dr. Andreasson’s laboratory developed genetically modified mice. These mice were engineered to allow for the targeted deletion of the EP2 gene specifically within tissue-resident macrophages at a time of the researchers’ choosing. The removal of EP2 effectively restored the macrophages’ phagocytic capacity, reversing the detrimental effects of excessive PGE2 signaling and restoring the efficient clearance of neutrophils.
The research team conducted a comparative analysis involving younger mice (6-8 months old), analogous to late adolescence or early adulthood in humans, and older mice (23-25 months old), comparable to individuals in their 60s or 70s. A critical comparison group consisted of similarly aged mice whose EP2 gene had been deleted in their tissue-resident macrophages during their "teenage" years (4-6 months old). The researchers identified 71 blood proteins whose levels were significantly altered in normal older mice. Strikingly, in the older mice with EP2-deficient macrophages, 59 of these proteins remained at levels characteristic of younger animals. This effect was particularly pronounced in proteins originating from the liver, an organ densely populated with tissue-resident macrophages and a major contributor to age-related changes in blood chemistry, influencing the body’s overall metabolic rate.
Normal aged mice exhibited a marked accumulation of senescent neutrophils in the liver, spleen, and bone marrow, with smaller increases observed in numerous other examined organs. In contrast, older mice whose tissue-resident macrophages lacked EP2 maintained lower neutrophil levels, consistent with those found in younger animals. Beyond cellular markers, these mice also displayed a more youthful phenotype, appearing leaner, more physically fit, with reduced visceral fat and increased muscle mass. Their organ function, assessed through various tests, mirrored that of young mice.
The benefits of EP2 deletion extended to cognitive and physical performance. The reduction of EP2 in tissue-resident macrophages led to decreased inflammation in multiple tissues, including the blood, liver, colon, heart, kidney, and hippocampus, a brain region critical for memory and spatial navigation. Older mice lacking functional EP2 receptors on these macrophages also demonstrated significantly improved physical capabilities, performing comparably to younger mice in tests of speed, balance, and grip strength. Their memory retention was also substantially enhanced, as evidenced by their performance in maze navigation and object recognition tasks, where they outperformed their similarly aged counterparts with intact EP2 function.
The quest for a therapeutic intervention hinges on the development of a drug that can selectively inhibit EP2 activity. While several existing medications modulate PGE2, they often lack the specificity required. Nonsteroidal anti-inflammatory drugs (NSAIDs), for instance, reduce PGE2 production, a mechanism through which they alleviate pain and inflammation. However, these drugs also interfere with other prostaglandins that have essential physiological roles, and PGE2 itself can exert beneficial effects through different receptor pathways. Therefore, the ideal therapeutic strategy would target the EP2 receptor responsible for the detrimental inflammatory cascade without broadly suppressing other crucial prostaglandin functions.
To test the viability of this targeted approach, the researchers administered an experimental EP2-inhibiting drug to 22-month-old mice for a period of two months. This intervention resulted in a significant reduction in both total neutrophil counts and the proportion of senescent neutrophils, bringing these levels closer to those observed in younger animals. Furthermore, in vitro experiments confirmed that while aging impairs the phagocytic capacity of tissue-resident macrophages, EP2 blockade effectively restored this crucial function.
Crucially, the study extended its investigation to human cells, examining a comprehensive database of liver tissue from individuals of varying ages and health statuses. The findings revealed patterns strikingly similar to those observed in mice. Older human livers exhibited increased neutrophil accumulation, a higher prevalence of senescent neutrophils, a decline in tissue-resident macrophage function, and elevated EP2 activity. These age-related changes were even more pronounced in diseased liver samples. This marks the first documented observation of these specific cellular and molecular changes in human tissues. The potential therapeutic implications of enhancing the body’s ability to clear senescent neutrophils are substantial, offering a promising avenue for combating age-related diseases. Dr. Andreasson emphasized the urgent need for a "safe drug" that can specifically block EP2 without disrupting upstream processes such as PGE2 synthesis.
About the Author
